Ascites reinfusion using the Rhodiascit apparatus—clinical experience and coagulation abnormalities

S. P. WILKINSON
B.Sc., M.B., M.R.C.P.

A. R. DAVIDSON
M.B., M.R.C.P.

J. HENDERSON

ROGER WILLIAMS
M.D., F.R.C.P.

The Liver Unit, King’s College Hospital and Medical School, London S.E.5

Summary

The results of twenty-four ascitic reinfusions in twenty patients, using the Rhodiascit procedure, are reported. The procedure was of no value in the management of patients with spontaneous functional renal failure, but was of considerable value in accelerating hospital discharge of patients with tense ascites but good renal function. Complications of the procedure were few, but tests of blood coagulation became abnormal, the most likely cause of which was deposition of fibrin on to the filtration membrane.

The Rhodiascit ascites reinfusion technique has been used in the management of ascites on twenty-four occasions in twenty patients. The indications for use of the procedure were diuretic-resistant ascites with spontaneous functional renal failure (five patients), diuretic-induced uraemia (two), Budd-Chiari syndrome (two), in order to accelerate discharge from hospital for socio-economic reasons (ten), and one patient with cirrhosis and non-functioning kidneys (due to chronic glomerulonephritis) on maintenance haemodialysis who had recently developed ascites (Table 1).

Diuretic-resistant ascites with spontaneous functional renal failure (Cases 1–5)

The diagnosis of functional renal failure was based on the findings of uraemia, a 24 hr urine volume < 500 ml, a urine sodium concentration < 10 mEq/l and a urine : plasma osmolality ratio of > 1:1. As is usually found with functional renal failure, these patients were resistant to diuretic therapy.

The procedure did not appear to be of any real value to these patients. Although ascites was at least partly relieved, all patients died within two weeks of the recirculation. Renal function was not improved by the reinfusion (Fig. 1) and since no diuresis occurred it was discontinued within 6 hr in all five cases (Table 1).

Diuretic-induced uraemia (Cases 6 and 7)

This diagnosis was made when uraemia was accompanied by a 24 hr urine volume > 1000 ml, a urine sodium concentration > 25 mEq/l, and a urine : plasma osmolality ratio > 1:1. Both patients had moderate ascites with mild encephalopathy
Budd-Chiari syndrome (Cases 8 and 9)

These two patients were particularly interesting. Case 8, a 27-year-old female with Budd-Chiari syndrome possibly induced by the contraceptive pill, had a packed red cell volume (PCV) of 63% at the time of presentation with gross ascites. However, measurement of red cell mass showed this to be normal whereas the plasma volume was markedly reduced (1·1 litre) which accounted for the high PCV. The low plasma volume was attributed to a redistribution of the extracellular fluid into the ascites compartment. She was given diuretics on admission but failed to respond. Following a 6-hr reinfusion the PCV fell to 49%, associated with a marked clinical improvement, and response to diuretics. A similar sequence of events was observed in the other patient (Case 9). Both of these patients were discharged from hospital, but unfortunately readmitted later with reaccumulation of ascites and a deterioration in liver function. A second reinfusion was carried out in each case but both patients died of hepatic failure within a week of the procedure.

For socio-economic reasons (Cases 10–19)

These patients all had good renal function (normal plasma urea and creatinine concentrations, Table 1), but marked ascites. Conventional diuretic therapy would have taken 2–3 months to relieve the ascites, accepting a daily weight loss of 0·5 kg, whereas each
The Rhodiascit apparatus

585

patient was discharged within 2 weeks of the reinfusion. The procedure was continued either until all ascites had gone or until the filtration membrane clogged. In one case (No. 13) 26 hr of continuous recirculation were performed. All patients had a good diuresis during reinfusion and the ultrafiltrate volume ranged from 2·5 to 18 l (Table 1).

Chronic renal failure (Case 20)

In this patient without urine output there is no other means of controlling ascites, and so far he is being treated by repeated reinfusion at approximately 3 monthly intervals. This patient’s uraemia remains well controlled on haemodialysis.

Complications of reinfusion

Complications were few. On six occasions body temperature rose by $>1^\circ$C (in one patient, Case 2, the procedure was discontinued because of a rigor). A fall in plasma sodium concentration by $>5$ mEq/l was observed on four occasions; in one, Case 3, the plasma sodium fell from 105 mEq/l to 87 mEq/l after a 6 hr reinfusion. Additional intravenous saline, as recommended by others (Benkemmoun, 1972) was not given to any patient in this series. There were no instances of pulmonary oedema, but the procedure was always discontinued after 6 hr if there was not a diuresis of $>500$ ml. Bleeding, hypotension and peritonitis were not seen as complications.

Abnormalities in coagulation

In the earlier cases in the series it was observed that the plasma prothrombin time often became prolonged following the Rhodiascit procedure. Detailed coagulation studies were therefore performed on six consecutive patients (Cases 6, 7, 8, 9, 13 and 19).

The prothrombin time and concentrations of fibrinogen, factor V (a ‘common pathway’ factor), factor IX (an ‘intrinsic pathway’ factor), and factor VII (an ‘extrinsic pathway’ factor) were measured on peripheral venous blood immediately before starting reinfusion and at 6 hr after commencing reinfusion. Fibrinogen, factors V, IX and VII were also measured in the ascitic fluid before and after concentration, both at the commencement of reinfusion and after 6 hr, samples being taken from the peritoneal catheter and the venous reinfusion line.

Assay methods

Prothrombin time

The ‘one-stage’ method was used, 0·1 ml of citrated plasma being added to 0·1 ml of a standard thromboplastin and the time taken to clot measured after addition of 0·1 ml of 0·025 M calcium chloride.

Fibrinogen (plasma)

This was measured by the weighing of the dried fibrin clot formed by addition of 0·025 M calcium chloride to citrated plasma. Fibrinogen could not be detected in ascitic fluid using this method.

Fibrinogen (ascitic fluid)

A clot is formed by addition to the sample of EACA in saline and thrombin in calcium chloride. The clot is dissolved by 1% sodium hydroxide and a reaction formed by addition of Biuret. Samples are read spectrophotometrically.

Factor V

The time for clotting of a solution containing substrate plasma, thromboplastin and test solution is noted after addition to 0·025 M calcium chloride.

Factor VII

This is similar to factor V but a factor VII deficient plasma is used.

Factor IX

The clotting time of a solution containing substrate plasma, test solution, platelet substitute and kaolin is noted after addition of 0·05 M calcium chloride.

Results

As shown in Fig. 2, the plasma prothrombin time invariably became more prolonged after 6 hr of recirculation (mean increase 6 sec, range 4–13). Plasma fibrinogen concentrations also fell (mean fall 54%, range 25–67%). Plasma levels of factors V, VII and IX fell with mean reductions of 15% (0–39%), 36% (10–65%) and 19% (11–29%) respectively (Fig. 3).

There was also evidence of loss of coagulation factors on to the filtration membrane. Concentrations in the fluid after passage across the membrane should be higher than those in the unconcentrated fluid. By measuring the total protein content of ‘pre- and post-membrane’ ascitic fluid, the degree of concentration of fluid was estimated, values ranging from 1·8 to 2·5. The absolute value of the coagulation factors in the ‘post-membrane’ fluid was therefore divided by the concentration factor to give the ‘corrected’ concentration. There was a marked difference between unconcentrated ascitic fluid concentrations and the corrected concentrated concentration of all factors measured. Thus, at the commencement of the procedure the following mean decreases were found: fibrinogen 61% (53–71%), factor V 68% (62–72%), factor VII 45% (10–62%) and factor IX 62% (43–71%). After 6 hr of recirculation the loss of coagulation factors continued, the following mean falls being found: fibrinogen 49% (48–50%), factor V 67%
(60–83%), factor VII 49% (20–60%) and factor IX 56% (37–73%) (Fig. 4).

In view of the pore size of the filtration membrane (mol. wt 45,000) it is unlikely that the loss of coagulation factors across it was due to filtration. It is well established that fibrin and other clotting factors may adhere to haemodialysis membranes (Lindsay et al., 1972), and so after completion of the Rhodiscit procedure the membrane was taken apart and examined for fibrin by both histochemical and immunofluorescent techniques. Dense deposits of fibrin were found on the membrane (Fig. 5a and b).

Thus adherence of coagulation factors to the filtration membrane might be an important factor in the pathogenesis of the changes in coagulation factor levels in the peripheral blood described above. Disseminated intravascular coagulation with thrombocytopenia, and a widespread haemorrhagic diathesis has also been reported as a rare consequence of the Rhodiscit procedure (Lévy, Buffet and Conard, 1973). No patient in the present series had any evidence of bleeding, but the findings suggest that the procedure should not be used in any patient with a recent history of bleeding or in patients with markedly abnormal tests of coagulation.
Fig. 5. (a) PTAH stain of scrapings from dialysis membrane to show dense deposits of fibrin (× 128); (b) as (a) but staining for fibrin by immunofluorescence (× 640).

References


Ascites reinfusion using the Rhodiascit apparatus—clinical experience and coagulation abnormalities
S. P. Wilkinson, J. Henderson, A. R. Davidson and Roger Williams

Postgrad Med J 1975 51: 583-587
doi: 10.1136/pgmj.51.598.583

Updated information and services can be found at:
http://pmj.bmj.com/content/51/598/583

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/